search
Shionogi
Trends
- 1Shionogi to pay $2 billion for rare disease startup▼Shionogi pays $2B to acquire a rare disease startup
Japanese drugmaker Shionogi has agreed to acquire a rare disease-focused biotech startup in a deal worth roughly $2 billion. The acquisition, reported by BioPharma Dive, signals Shionogi's push to expand beyond its core infectious disease business into rare and specialty medicines, as larger pharma companies continue buying up innovative biotech pipelines.
- 2Shionogi to buy rare disease startup IntraBio for $2 billion▼Shionogi acquires rare disease startup IntraBio for $2 billion
Japanese pharmaceutical company Shionogi has agreed to acquire IntraBio, a biotech startup focused on rare diseases, in a deal valued at $2 billion. The move signals Shionogi's push to expand its pipeline into rare disease treatments. The acquisition is drawing attention as one of the larger biotech deals targeting niche therapeutic areas.